ENSEM: Ensem Therapeutics' application for ETX-636 secures FDA clearance

This allosteric pan-mutant-selective phosphatidylinositol 3-kinase alpha (PI3Kα) inhibitor and degrader is poised to enter first-in-human trials in the second quarter of this year. According to the company, mutant The post Ensem Therapeutics' application for ETX-636 secures FDA clearance appeared first on Pharmaceutical Business review.